Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use.
about
Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilizationFetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategies.HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating TregsManagement of a pregnant woman with common variable immunodeficiency and previous reactions to intravenous IgG administration.Therapeutic plasma proteins--application of proteomics in process optimization, validation, and analysis of the final product.Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects.Subcutaneous immunoglobulins for the treatment of a patient with antisynthetase syndrome and secondary chronic immunodeficiency after anti-CD20 treatment: a case report.Biologics in dermatology: adverse effects.Long-Term Treatment and Transfusion of Normal Blood Components Following Tolerance Induction in Patients with Anti-IgA Anaphylactic Reactions.Surveillance study on the tolerability and safety of Flebogamma® DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients.Occurrence of hemolytic reactions on the same day as immune globulin product administrations during 2008 to 2014.Intravenous immunoglobulin-induced acute thrombocytopenia.Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.
P2860
Q26741124-6959DA1B-0C46-40FC-B2C9-53AAA62E322EQ33442939-7E61A1BC-D750-44B1-A64D-DDCA77241ADEQ33786811-7C71B2D7-5C8B-45F4-8173-D271FC8FC2D9Q35979722-77F685F5-07B2-47FF-B61B-399D10803DC5Q37872258-504F1905-7AD4-43C9-B2B2-9CDD13CE86CEQ38111424-41BB40B7-E928-4355-8369-D6CDF53C347BQ40309531-06B4C034-9260-4C14-BF67-A56E5898BF5FQ41120913-F2FB9808-9D5B-45E5-9E0F-B771115C97B8Q41808658-AE956D0A-BD8E-40F9-BC25-98F5DC235893Q42183204-43C9D89E-BAC9-42EE-AB83-2B880C31C906Q45072412-013EF1C8-47E9-4759-9BA7-293739549E90Q48203712-23BF70EC-99AD-456A-99E6-B2D427D4247EQ50231116-D5F428EE-BC27-4658-88C8-6B0590D68AAE
P2860
Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Relevant criteria for selectin ...... preparation for clinical use.
@en
Relevant criteria for selectin ...... preparation for clinical use.
@nl
type
label
Relevant criteria for selectin ...... preparation for clinical use.
@en
Relevant criteria for selectin ...... preparation for clinical use.
@nl
prefLabel
Relevant criteria for selectin ...... preparation for clinical use.
@en
Relevant criteria for selectin ...... preparation for clinical use.
@nl
P2860
P1433
P1476
Relevant criteria for selectin ...... preparation for clinical use.
@en
P2093
Jean Cabane
Patrick Chérin
P2860
P304
P356
10.2165/11537660-000000000-00000
P577
2010-08-01T00:00:00Z
P6179
1042481619